ANZCTR - Registration

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12621000878875

Ethics application status

Approved

Date submitted

2/06/2021

Date registered

7/07/2021

Date last updated

15/05/2023

Date data sharing statement initially provided

7/07/2021

Date results provided

15/05/2023

Type of registration

Prospectively registered

Titles & IDs

Public title

Is metformin better taken before or with meals? An acute evaluation of the impact of timing of metformin administration on intestinal glucose absorption, gut hormone secretion and the blood glucose response to an intraduodenal glucose infusion in type 2 diabetes

Scientific title

Secondary ID [1]

Nil

Universal Trial Number (UTN)

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Type 2 diabetes

Condition category

Condition code

Metabolic and Endocrine

Diabetes

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Following enrolment, each subject will be studied on 4 occasions, separated by at least 7 days, in a double-blind, randomized, crossover design with treatment allocation assigned by the Royal Adelaide Hospital Pharmacy. During the study period, patients will only need to cease their morning dose of metformin on the respective study days to allow for evaluation of the impact of timing of metformin administration on the study outcomes. On the evening preceding the study day (~1900h), participants will be given a standardised evening meal (McCain’s frozen beef lasagne (McCain Foods Proprietary Ltd, Victoria, Australia); 2472kJ) to consume with water. Following this meal, participants will be asked to fast from solids and liquids (water will be allowed until 10 pm) until the following morning, when they will attend the CRF of the AHMS building at 0800h.

On each study day, a silicone rubber catheter (Dentsleeve International Ltd., Mui Scientific, Ontario, Canada) will be inserted through an anaesthetised nostril into the stomach, and allowed to pass into the small intestine by peristalsis. The catheter will be positioned with the intraduodenal infusion port located 12 cm distal to the pylorus. The correct positioning of the catheter will be monitored continuously by measurement of the transmucosal potential difference in the stomach (~ -40 mV) and the duodenum (~ 0 mV). For this purpose, an intravenous cannula will be placed subcutaneously in the left forearm and filled with sterile saline as a reference electrode. An intravenous cannula will be placed into a vein on the dorsum of the hand, which will be kept warm with a heat pad to allow sampling of “arterialised” blood.

After correct positioning of the catheter, 1000 mg metformin dissolved in 30 mL water, or 0.9% saline as a control, will be administered intraduodenally over 2 min at t = -60, -30 or 0 min, in a double-blind, randomised fashion, i.e. one of the following 4 treatments:
(i) 1000 mg metformin at t = -60 min + 0.9% saline at t = -30 and 0 min,
(ii) 1000 mg metformin at t = -30 min + 0.9% saline at t = -60 and 0 min,
(iii) 1000 mg metformin at t = 0 min + 0.9% saline at t = -60 and -30 min, or
(iv) 0.9% saline at t = -60, -30 and 0 min.
Commencing at t = 0 min, a solution containing 45 g glucose and 5g 3-OMG (as a marker of intestinal glucose absorption) dissolved in water to a total volume of 180 mL, will be infused into the duodenum over 60 minutes (i.e. 3 kcal/min). At t = 60 min, the catheter will be removed. The participant will be monitored for another 60 min (t = 60 - 120 min) before a light meal is served.

“Arterialised” venous blood (~10 mL) will be sampled at t= -60, -30, 0, 30, 60, 90, 120 min. Blood glucose levels will be measured immediately at the bedside with a glucometer (Medisense Precision QID, Abbott Laboratories, Bedford, MA, USA). Plasma and serum samples will be separated from the remainder of each sample and stored at -80 degree Celsius for subsequent measurements. At the same intervals used for blood sampling, appetite and gastrointestinal sensations (including hunger, desire to eat, fullness, nausea, bloating, headache and abdominal pain) will be assessed using 100 mm visual analogue scales. After a final blood sample is collected, subjects will be served with a light lunch, and once the blood concentrations of subjects have stabilised above 5 mmol/L, subjects will be free to leave the laboratory. The total amount of blood drawn during the screening and 4 study visits will be ~300 mL.

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

Placebo controlled - participants will act as their own control in this cross-over study. Placebo will be 0.9% saline

Control group

Placebo

Outcomes

Primary outcome [1]

The differences in the iAUC0-120min for serum 3-OMG concentrations between treatments.

Timepoint [1]